Related Experiment Video

Updated: Oct 5, 2025

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
09:03

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

487

Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells

YanWei Li1,2,3, Feng He1,2, Yu Zhang3

  • 1Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin 300192, China.

Disease Markers
|January 24, 2022
PubMed
Abstract

Insights

Combining apatinib and Ginsenoside-Rb1 (G-Rb1) shows synergistic anticancer effects against hypopharyngeal carcinoma. This combination therapy inhibits tumor growth, reduces cell proliferation, and enhances antitumor immunity.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Apatinib targets VEGFR-2, but drug resistance is a concern.
  • Ginsenoside-Rb1 (G-Rb1) is a traditional Chinese medicine.
  • The synergistic anticancer effects of apatinib and G-Rb1 in hypopharyngeal carcinoma have not been previously studied.

Purpose of the Study:

  • To investigate the combined anticancer effects of G-Rb1 and apatinib in hypopharyngeal carcinoma.
  • To evaluate the impact of combination therapy on tumor growth, cell behavior, and immune response.

Main Methods:

  • Studied effects on cell proliferation, wound healing, migration, and apoptosis in hypopharyngeal carcinoma cells.
  • Utilized a xenograft rat model to assess tumor inhibition with mono- and combination therapy.
  • Analyzed protein expression and localization via western blotting and immunofluorescent staining.

Main Results:

  • Combination therapy significantly inhibited cancer cell proliferation, migration, and wound healing.
  • Combined treatment decreased cellular glycolysis, leading to reduced tumor growth.
  • Tumor size was dramatically reduced in xenograft rats receiving combination therapy.
  • Enhanced counts of CD3+, CD4+ T cells and an increased CD4+/CD8+ T cell ratio were observed.

Conclusions:

  • Apatinib and G-Rb1 combination therapy induces greater tumor cell apoptosis and reduces proliferation compared to individual treatments.
  • The combination promotes antitumor immunity through enhanced immunomodulatory molecules.
  • This study provides a platform for assessing synergistic effects of synthetic and herbal medicines.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.2K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
282
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
275